Control of CD8+ T cell migration and activation by Flightless-1
Project Number5R21AI157440-02
Contact PI/Project LeaderCAMPBELL, DANIEL J
Awardee OrganizationBENAROYA RESEARCH INST AT VIRGINIA MASON
Description
Abstract Text
PROJECT SUMMARY
Adaptive immune surveillance depends on the ability of T cells to successfully migrate through secondary
lymphoid tissues and form immune-synapses with antigen-presenting cells. Precise and dynamic organization
of the actin cytoskeleton is essential for both of these processes. In migrating T cells rapid reorganization of the
actin cytoskeleton is essential for cell polarization and chemotactic responses required for tissue entry and
proper micro-environmental positioning. During T cell activation, changes in the actin cytoskeleton control proper
formation of the immunological synapse, a highly organized cellular structure that allows T cells to properly
integrate signals from the T cell receptor with those from co-stimulatory molecules such as CD28 and integrins
such as LFA-1 (αLβ2). Flightless-1 (Flii) was initially identified in Drosophila as an actin modifying protein that
controls actin myofibril structure in the muscles that control flight. Flii contains an N-terminal leucine-rich repeat
(LRR) domain that facilitates protein-protein interaction and has been implicated in control of Ras activation of
Erk/Mapk signaling, Rac1 activation and PI3K signaling. The Flii C-terminus encodes 6 gelsolin-related domains
that can interact with actin and regulate actin filament assembly/disassembly. Based on its unique domain
structure, we hypothesize that Flii acts as a key regulator of CD8+ T cell homeostasis and function by linking
changes in the actin cytoskeleton during cell migration and activation with spatial control of various signaling
cascades. We will use state-of-the-art cellular and molecular techniques to study Flii function in physiologically
relevant and innovative mouse models. Completion of these studies will provide important new insights into a
novel and completely uncharacterized signaling hub that regulates CD8+ T cell-mediated immunity.
Public Health Relevance Statement
PROJECT NARRATIVE
We hypothesize that Flightless-I (Flii) links changes in the actin cytoskeleton to the activation and spatial
organization of key signaling pathways during T cell migration and activation, and thereby acts as a key and
completely uncharacterized regulator of CD8+ T cell responses. Using Flii conditional knockout mice, we will
determine how Flii regulates actin dynamics and spatial control of key signaling pathways during T cell migration
and activation, and to determine how this impacts CD8+ T cell responses in vivo.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
076647908
UEI
PK9FMGRDRVD5
Project Start Date
05-March-2021
Project End Date
28-February-2023
Budget Start Date
01-March-2022
Budget End Date
28-February-2023
Project Funding Information for 2022
Total Funding
$217,625
Direct Costs
$125,000
Indirect Costs
$92,625
Year
Funding IC
FY Total Cost by IC
2022
National Institute of Allergy and Infectious Diseases
$217,625
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R21AI157440-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21AI157440-02
Patents
No Patents information available for 5R21AI157440-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21AI157440-02
Clinical Studies
No Clinical Studies information available for 5R21AI157440-02
News and More
Related News Releases
No news release information available for 5R21AI157440-02
History
No Historical information available for 5R21AI157440-02
Similar Projects
No Similar Projects information available for 5R21AI157440-02